Since immune cell checkpoints are key targets for cancer treatment using immune checkpoint blockade (ICB), several checkpoint molecules, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 (PD-1), and programmed cell death-ligand 1 (PD-L1) were evaluated. Here, CTLA4 is linked to cancer.